PRESS RELEASES
11-Feb-21
ReNetX Founder Steve Strittmatter Wins 2021 King Faisal Prize for Medicine
ReNetX Founder Steve Strittmatter Wins 2021 King Faisal Prize for Medicine
13-Jan-21
ReNetX Bio Adds Financial Expertise to its Board of Directors, Appointing Sean Cassidy, MBA
ReNetX Bio Adds Financial Expertise to its Board of Directors, Appointing Sean Cassidy, MBA
22-Oct-20
ReNetX Bio Awarded $3M SBIR Phase II Grant to Advance Treatment for Chronic Spinal Cord Injury
ReNetX Bio Awarded $3M SBIR Phase II Grant to Advance Treatment for Chronic Spinal Cord Injury
25-Sep-20
ReNetX Adds Strategic Drug Development Regulatory Expert to Scientific Advisory Board
ReNetX Adds Strategic Drug Development Regulatory Expert to Scientific Advisory Board
13-Jul-20
ReNetX Bio Announces Key Scientific Publication Validating Preclinical Translation with Lead Molecule
ReNetX Bio Announces Key Scientific Publication Validating Preclinical Translation with Lead Molecule
08-Jan-20
ReNetX Bio Receives Fast Track Designation From U.S. FDA
ReNetX Bio Receives Fast Track Designation From U.S. FDA
More Press Releases
19-Jun-19
ReNetX Bio, Inc. Announces U.S. FDA Authorization to Proceed for IND Application to Treat Patients with Chronic Spinal Cord Injury
ReNetX Bio, Inc. Announces U.S. FDA Authorization to Proceed for IND Application to Treat Patients with Chronic Spinal Cord Injury
07-May-18
New Haven-Based ReNetX Bio, Inc. Closes Series A Funding and Expands Upon New Haven Roots
New Haven-Based ReNetX Bio, Inc. Closes Series A Funding and Expands Upon New Haven Roots
10-Apr-18
ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium
ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium
07-Nov-17
ReNetX Bio Receives $7M Commitment from Wings for Life to Bring Spinal Cord Treatment to Trial
ReNetX Bio Receives $7M Commitment from Wings for Life to Bring Spinal Cord Treatment to Trial
10-Oct-17
Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board
Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board
24-Jul-17
ReNetX Bio Launched to Advance Innovative Neuro-Regenerative Technology Developed at Yale University: Company Appoints Erika R. Smith as CEO
ReNetX Bio Launched to Advance Innovative Neuro-Regenerative Technology Developed at Yale University: Company Appoints Erika R. Smith as CEO
IN THE MEDIA
10-Dec-19
Erika Smith of ReNetX Named 2019 BioCT Entrepreneur of the Year
Erika Smith of ReNetX Named 2019 BioCT Entrepreneur of the Year
28-Oct-19
Shepherd Center Treats Two Patients with Chronic Spinal Cord Injury with Potential Restorative Drug in RESET Clinical Trial
Shepherd Center Treats Two Patients with Chronic Spinal Cord Injury with Potential Restorative Drug in RESET Clinical Trial
More News
01-Sep-19
Erika Smith Honored with New Haven BIZ 2019 Innovation Award
Erika Smith Honored with New Haven BIZ 2019 Innovation Award
28-Jun-19
Murphy Highlights New Haven's ReNetX Bio as "Murphy's Innovator of the Month"
Murphy Highlights New Haven's ReNetX Bio as "Murphy's Innovator of the Month"
27-Jul-17
Yale Scientist Aiming To Reverse Spinal Cord Injuries
Yale Scientist Aiming To Reverse Spinal Cord Injuries
25-Jul-17
Drug Aims to Help Treat Spinal Cord Injuries
Drug Aims to Help Treat Spinal Cord Injuries
INTERVIEWS
Meet Dr. Stephen Strittmatter
Founder of ReNetX Bio
Professor of Neurology & Neuroscience, Yale School of Medicine
|
New Haven Register, Aug 4, 2017 by Ed Stannard
Dr. Stephen Strittmatter talks about a new therapy to repair severed nerves in the central nervous system |
© 2021 ReNetX Bio, Inc. All Rights Reserved.
|